Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug Pioglitazone Hydrochloride Dispersible Tablets, which is expected to enhance market competitiveness and sales potential in the future [1][2]. Group 1: Drug Approval and Development - The company’s subsidiary, Shuanghe Tianan Pharmaceutical, received the approval notice for Pioglitazone Hydrochloride Dispersible Tablets from the National Medical Products Administration [1]. - The consistency evaluation for this drug began in 2017, with the application submitted in December 2024 and approval received in November 2025 [2]. - The total R&D investment for this drug's consistency evaluation has reached RMB 8.8227 million (unaudited) [2]. Group 2: Market Situation of Similar Drugs - Pioglitazone tablets, developed by Takeda Pharmaceutical, were approved in the U.S. in July 1999 and in China in 2004, but have since been withdrawn from the market [3]. - The global sales of Pioglitazone tablets are projected to be USD 254 million in 2024, with "ACTOS" contributing USD 41.6958 million [3]. - In China, the total sales of Pioglitazone tablets in the medical and retail markets are estimated at RMB 349 million in 2024, with Shuanghe Tianan holding a market share of 10.46% [3].

Core Viewpoint - The article highlights the transformation of China Resources Double Crane into a leading pharmaceutical group through smart manufacturing, strategic acquisitions, and international expansion, particularly in the medical infusion sector and innovative drug development [1][3][8]. Group 1: Smart Manufacturing - Henan Double Crane Huali Pharmaceutical Co., a subsidiary of China Resources Double Crane, has achieved a production speed of nearly 800 bottles (bags) per minute, positioning itself as a benchmark in the medical infusion industry [1][4]. - The company has implemented a fully automated production line, achieving "unmanned" operations throughout the entire process, which has led to a 15% to 20% increase in production efficiency and a 10% to 15% rise in daily output [4][5]. - The intelligent warehouse, with a capacity of approximately 50 million bottles (bags), is the largest modern smart warehouse in Henan Province, further enhancing operational efficiency [4]. Group 2: Strategic Acquisitions - China Resources Double Crane has a strong track record in acquisitions, having acquired companies like Shenzhou Biological, Tianan Pharmaceutical, and Huaren Zizhu to diversify its product portfolio and expand beyond infusion products [6]. - The recent acquisition of Zhongshu Pharmaceutical allows the company to enter the psychotropic drug market, with expectations for significant revenue growth from its core product, which is anticipated to reach a billion-level market size by 2025 [6][7]. - The company is focusing on acquiring leading firms in high-growth areas such as mental health, ophthalmology, and pediatrics, while also enhancing its biomanufacturing capabilities [7]. Group 3: International Expansion - China Resources Double Crane aims to shift from raw material exports to finished product exports, emphasizing product differentiation as a key strategy for international markets [8]. - The company plans to establish an international business department to coordinate its global operations and enhance its competitive edge in the international pharmaceutical market [8]. - Future international strategies include leveraging the Hainan Free Trade Port's advantages to create a global health production base and pursuing overseas acquisitions, particularly in Europe and the U.S. [8].

Core Viewpoint - The company is advancing its smart manufacturing capabilities, enhancing production efficiency and competitiveness through automation and digitalization, while also focusing on innovation and international expansion in the pharmaceutical sector [2][3][4]. Group 1: Smart Manufacturing and Automation - The new facility emphasizes automation, digitalization, and intelligent design, incorporating advanced equipment such as AI inspection machines and integrated filling machines, achieving industry-leading smart manufacturing levels [3]. - Production efficiency has increased by 15% to 20%, with daily output rising by 15%, significantly enhancing competitiveness [3]. - Since relocating in 2021, overall production capacity has surged by 346% without increasing labor costs, resulting in a 310% rise in per capita labor productivity [3]. Group 2: Digital Transformation - The company has accelerated its digital transformation, achieving an 85% digital coverage rate in key business areas and receiving recognition as an "Excellence Level Smart Factory" [4]. - The digital transformation supports operational excellence and innovation, aligning with the company's strategic goals [4]. Group 3: Product and Market Expansion - The company is committed to low-cost, large-scale, multi-product, innovative, and high-quality strategies, focusing on developing products that better serve clinical needs [6]. - The acquisition of global commercialization rights for a new diabetes treatment marks a significant advancement in addressing unmet medical needs in the diabetes foot ulcer market [6]. Group 4: Innovation and R&D Strategy - The company aims to balance generic and innovative drug development, utilizing a "License-out" strategy to manage R&D costs and enhance quality while expanding international presence [7]. - Mergers and acquisitions are pivotal for expanding the product portfolio and driving innovation, with a focus on leading companies in niche markets and biomanufacturing [8]. Group 5: Synthetic Biology and Future Growth - The company has established a "raw material and formulation integration" strategy, acquiring biopharmaceutical firms to enhance profitability through synthetic biology technologies [9]. - The synthetic biology research institute has been set up to drive innovation, with several products already in the pilot testing phase, focusing on raw materials and specialty formulations [10]. Group 6: Strategic Goals and Internationalization - The company aims to become the leading brand in prescription drugs in China, with plans to enhance brand influence and expand its product pipeline through strategic acquisitions [11]. - Internationalization is viewed as a key pathway for achieving strategic goals, transitioning from raw material exports to finished product exports to enhance competitiveness in the global market [11].

发酵车间（呼和浩特市科学技术局供图） 呼和浩特依托独特的资源禀赋与要素比较优势，合力打造以合成生物为特色的生物医药产业集群，形成生物发酵、生物疫苗、中（蒙）医药完整产业链条。 目前，全市规上工业企业34家，累计获得药品注册批件602个，产业集聚效应与发展活力持续凸显。此次5亿产业基金的落地，将进一步推动首府生物医药产 业补链延链固链强链，加速推动打造国内领先的合成生物产业标杆城市。 此次基金的正式落地，不仅为呼和浩特生物医药产业注入新的资金与资源动能，更让当地合成生物产业再次站上战略风口。未来，随着基金投资项目的逐步 落地与赋能效应的释放，呼和浩特市有望加速实现从"资源优势"向"发展优势"的转型升级，进一步缩短与全国顶尖生物医药产业集群的差距，为打造全国领 先的生物医药产业高地奠定坚实基础。（来源：呼和浩特市科学技术局） 从定位来看，该基金为"产业赋能型投资平台"，不仅对企业提供资金支持，也将依托华润集团在大健康、科技与新兴产业、大消费等多元化的产业基础和资 源，加之呼和浩特市在合成生物产业上的政策、资源、载体三位一体的发展优势，为当地企业提供从技术研发、中试转化、产能落地到市场拓展的全链条赋 能和支持，促进 ...

Core Viewpoint - China Resources Double Crane Pharmaceutical (600062.SH) announced that its subsidiary, Double Crane Tianan Pharmaceutical (Guizhou) Co., Ltd., received approval from the National Medical Products Administration for the supplementary application of Pioglitazone Hydrochloride Dispersible Tablets, which is considered to have passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The approved drug, Pioglitazone Hydrochloride Dispersible Tablets, is used for the treatment of type 2 diabetes [1] - The successful consistency evaluation is expected to enhance future market sales and competitiveness for the company [1] - This achievement will also provide valuable experience for the company in conducting future evaluations of generic drug consistency [1]

Core Viewpoint - China Resources Double Crane Pharmaceutical (600062.SH) announced that its subsidiary, Double Crane Tianan Pharmaceutical (Guizhou) Co., Ltd., received the approval notice for the supplementary application of Pioglitazone Hydrochloride Dispersible Tablets from the National Medical Products Administration, indicating that the drug has passed the consistency evaluation for generic drug quality and efficacy [1] Group 1 - The approved drug, Pioglitazone Hydrochloride Dispersible Tablets, is used for the treatment of type 2 diabetes [1] - The successful consistency evaluation is expected to enhance future market sales and competitiveness for the company [1] - This achievement will also provide valuable experience for the company in conducting future evaluations of generic drug consistency [1]

Core Viewpoint - China Resources Double Crane announced that its subsidiary, Double Crane Tianan Pharmaceutical Co., Ltd., received the approval notice for the supplementary application of Pioglitazone Hydrochloride Dispersible Tablets from the National Medical Products Administration [1] Summary by Categories - **Regulatory Approval** - The company has received a supplementary application approval for Pioglitazone Hydrochloride Dispersible Tablets from the National Medical Products Administration [1] - **Research and Development Investment** - As of the date of the announcement, the total R&D investment for this drug's consistency evaluation amounts to RMB 8.8227 million (unaudited) [1]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－100 华润双鹤药业股份有限公司 关于控股子公司双鹤天安药业(贵州)股份有限公司 盐酸吡格列酮分散片获得药品补充申请批准通知书的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")控股子公 司双鹤天安药业(贵州)股份有限公司(以下简称"双鹤天安")收到了 国家药品监督管理局(以下简称"国家药监局")颁发的盐酸吡格列酮 分散片(以下简称"该药品")《药品补充申请批准通知书》。现将相 关情况公告如下： | 申请内容 | 仿制药质量和疗效一致性评价 | | --- | --- | | 审批结论 | 根据《中华人民共和国药品管理法》、《国务院 号) | | | 关于改革药品医疗器械审评审批制度的意见》(国 | | | 发〔2015〕44 号)和《关于仿制药质量和疗效一致 | | | 性评价工作有关事项的公告》(2017 年第 100 | | | 规定，经审查，本品视同通过仿制药质量和疗效 | | | 一致性评价。 ...

Core Insights - The 2025 National Consumption Conference was held in Beijing, showcasing innovative consumption cases for 2025 [1] Company Innovations - Guizhou Zhenjiu focuses on quality and channel expansion to drive consumption growth [3] - Herbalife transitions from liquid nutrition to solid food with cake premix, promoting a blend of taste and health [3] - Weigang Dairy upgrades its formula and processes, venturing into new tea drinks [3] - Yilian integrates lotus culture with hyaluronic acid technology for innovative consumer experiences [3] - Aishurou emphasizes the transmission of "emotional value" for a clean and beautiful lifestyle [3] - TAIC introduces pure titanium home products, enhancing aesthetic living experiences [3] - Yalong Xiaoxiang explores new models for cultural relics through smart trade routes [3] Service Consumption - Pudong Development Bank Credit Card deepens customer engagement with running series to boost sports consumption [3] - Mars Petcare collaborates with Beijing Fashion Week to create a new fashion for pet owners [3] - Joy City empowers emotional connections through digital membership ecosystems [3] - Daguan Zhuanxin New Agricultural Market innovates highland agricultural product consumption scenarios with a three-tier product operation model [3] - Baiguoyuan enhances trust in consumption services with a "buy with confidence, return at will" policy [3] - Taikang focuses on elderly dental care needs with "Worry-Free Insurance" providing full-cycle services [3] - Koala AI Foreign Teacher leverages AI to enhance language learning experiences [3] - Vision Future utilizes AI digital technology to support a new ecosystem for live e-commerce [3] Brand Leadership - Zhanma transitions from a "traffic entry" to a "brand territory," enhancing brand influence [3] - Shuanghui Jian Song creates a new trend in self-care consumption with "clean formulas" [3] - Bright Dairy achieves brand upgrades from "national memory" to "trend symbols" through three-dimensional innovation [3] - Bosideng innovates technology in down jackets, balancing functionality and fashion [3] - Jinmailang Liangbai Kai strengthens health awareness in familiar water, promoting brand philosophy [3] - Mead Johnson Blue Zhen adheres to research innovation, using milk fat globule membrane to support high-quality industry development [3] - Hengjie explores new paths for domestic brands with the "Renew China Tour" IP [3] - Seven Wolves introduces new business travel menswear, culturally empowering national consumption trends [3] - Guyu innovates the interaction between science and aesthetics, narrating brand stories through traditional culture [3] Product Reputation - Haizhilun anchors on popular drinking scenarios, continuing quality innovation to maintain classic reputation [4] - Feihe Star Flying Sail creates a "fresh nutrition system" for a new generation of baby food [4] - Guangzhou Restaurant Lychee Pastry connects with Cantonese food culture, offering a new paradigm for "Guangzhou gifts" [4] - Hongxing Erke Park Running Shoes focuses on national sports scenarios, driving innovative domestic consumption [4] - Xiaohutuxian·Xian15 upgrades classic products, enhancing quality and cultural experience [4] - Pigeon newborn bottles address feeding pain points, optimizing feeding methods [4] - Beishute's "plant-based" sanitary napkins provide comprehensive safety from source to end [4] - Mingyue Qingsong control lenses innovate optical technology for a more comfortable visual experience [4] - FreeSkin hand cream innovates services to create a "high quality-price ratio" trend for domestic products [4] - Dong'a Ejiao advances technology to promote the integration of primary, secondary, and tertiary industries, creating trendy quality domestic products [4] - Dili Group empowers agricultural product circulation with technology and services [4] - Atomy drives continuous product upgrades through a "boutique" strategy and technological innovation [4] Green Consumption - China Resources Double Crane targets "dual carbon" goals, offering low-carbon products for a green lifestyle [5] - Amcor's "green and eco-friendly actions" bring sustainable development into practice [5] - Meisi's "green bottle" ensures sustainable high-quality consumption [5] - Laitai Mootaa leverages technology and green empowerment to explore new consumption experiences [5] - IAM's core technology eliminates the need for replacement consumables, supporting green and safe breathing [5] - Procter & Gamble identifies new consumer needs, providing high-quality laundry liquids for a better life [5] - OgaHua's massage robots utilize AI to enhance comfort in daily living [5] - Banfish PalFish integrates smart home with traditional aesthetics through full-spectrum eye protection lamps [5] - Huangshi Group revitalizes water buffalo milk products to meet high-quality dairy consumption demands [5] - Lemon Republic creates a new beverage experience with "cloud mist lemon" juice soda [5]

Group 1: US Market Overview - US stock market experienced a four-day rally, with the Dow Jones up 0.67%, Nasdaq up 0.82%, and S&P 500 up 0.69% [1] - Notable stock performances include Microsoft up 1.78%, Tesla up 1.71%, Nvidia up 1.37%, while Amazon down 0.22%, Meta down 0.40%, and Google A down 1.08% [1] Group 2: Economic Indicators - Initial jobless claims in the US fell to 216,000, the lowest since mid-April [2] - The Federal Reserve's Beige Book indicates a further decline in overall consumer spending in the US in recent weeks [3] Group 3: International Developments - The US special envoy is engaged in negotiations to promote peace talks between Russia and Ukraine, with Trump noting significant progress but no deadline [4] - Japan and the US are considering building a public-private partnership NAND factory in the US [5] - South Korea successfully launched its self-developed carrier rocket "World" [6] Group 4: Domestic Policy and Industry Developments - Six Chinese departments, including the Ministry of Industry and Information Technology, issued a plan to enhance the adaptability of supply and demand in consumer goods, promoting new business models like live e-commerce and instant retail [8] - The technology sector is showing signs of recovery, which may lead to a continued rebound in market sentiment [9] Group 5: Industry Insights - In the photovoltaic sector, notable performances include Canadian Solar up 8.4% and Daqo New Energy up 3.2%, with polysilicon futures rising nearly 3% to a recent high [10] - The organic silicon industry is seeing price increases of 10-20% for major products starting December 10, with a significant expansion in production capacity expected [11] - The automotive industry is focusing on the integration of vehicle and road cloud systems, with a current vehicle connectivity rate exceeding 85% [11] - The paper industry is experiencing price increases, with packaging paper rising by approximately 50 CNY/ton and cultural paper by 200 CNY/ton [12][14] Group 6: Company Announcements - Tian Shan Aluminum announced the commissioning of its first batch of electrolytic cells for a green low-carbon efficiency enhancement project [16] - Yidong Electronics plans to invest 61.2 million CNY to acquire a 51% stake in Shenzhen Guanding, focusing on AI server liquid cooling products [18] - Industrial Fulian adjusted its share repurchase price limit from 19.36 CNY to 75 CNY per share [18]